Sponsored by:
Optimizing Excipients for Biologic Therapies Delivered via Inhalation
The shift toward biologics delivered via the respiratory route is accelerating—and with it comes the need for precision in excipient selection. Whether in nebulized liquids or dry powder inhalers, biologics demand tailored formulation strategies to ensure safety, stability, and therapeutic effectiveness.
This expert white paper, authored by scientists at Lonza Small Molecules, examines:
- The current landscape of respiratory-delivered biologics.
- How excipients influence the physical and chemical stability of proteins, peptides, and nucleic acids.
- Regulatory considerations based on FDA’s Inactive Ingredient Database (IID).
- Formulation strategies for both liquid and dry powder inhalation therapies.
Whether you're a formulation scientist, regulatory expert, or business leader in biotech, this white paper offers crucial insights into the evolving world of inhaled biologics.
